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Abstract
Transthyretin/TTR gene mutations usually cause systemic amyloidotic diseases. Few TTR variants preferentially affect
the central nervous system, manifesting as oculoleptomeningeal amyloidosis. Patients with TTR meningovascular
amyloidosis often show dementia, however the neuropathologic features of dementia in these cases have not
been elucidated. We report the neuropathologic findings from a brain autopsy of a 72-year-old man with the rare
Tyr69His (Y69H) TTR gene variant, dementia and ataxia. Severe amyloid deposits were observed in the leptomeninges
and in a subpial and subependymal distribution. Mass spectrometry analysis demonstrated that the amyloid deposits
were comprised of over 80 % of the variant TTR. TTR was undetectable by mass spectrometry in the neocortex
subjacent to the subpial amyloid deposits. Subpial TTR amyloid deposits were associated with brisk superficial
reactive gliosis and siderosis in the neocortex and cerebellar cortex. Subependymal TTR amyloid deposits were
associated with subjacent myelin pallor in the hippocampal outflow tract structures including the alveus, fimbria
and fornix. Phospho-tau immunostains demonstrated transentorhinal-stage neurofibrillary degeneration (Braak
stage II) which, in the absence of neocortical amyloid-beta and neuritic plaques, was indicative of primary age-related
tauopathy (PART). However, distinctive phospho-tau aggregates were observed subjacent to the subpial TTR amyloid
deposits in all regions of the neocortex, including the primary motor and striate cortices, suggesting a potential link
between TTR amyloid and neocortical tauopathy. Our report reveals novel insights into the potential neuropathologic
substrates of dementia in variant TTR amyloidosis that need to be investigated in larger autopsy series.
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Background
Transthyretin (TTR) is a soluble protein tetramer that car-
ries thyroxine and retinol binding protein in the circula-
tion [1]. Insoluble TTR amyloid deposition is most
commonly seen as a systemic disease in elderly individuals
[2]. Patients with TTR mutations also most often present
with systemic amyloidotic diseases including familial amy-
loidotic polyneuropathy (FAP) [3] and familial amyloid
cardiomyopathy [2]. Mild cerebral TTR amyloid angio-
pathy and choroid plexus amyloidosis can be observed
in systemic amyloidotic diseases like FAP [4, 5]. In
contrast, severe meningovascular amyloidosis is associated
with certain TTR gene mutations, including Leu12Pro [6],
Asp18Gly [7, 8], Ala25Thr [9, 10], Val30Gly [11–13], Val30-
Met [14, 15], Thr49Pro [16], Leu58Arg [17], Phe64Ser [18],
Tyr69His [19–21] and Tyr114Cys [22], and can lead to
dementia and ataxia. To gain potential insights into the
pathogenesis of these deficits in meningovascular amyloid-
osis, we report our postmortem neuropathologic findings
from a patient with dementia, ataxia and the rare Tyr69His
(Y69H) TTR substitution.
Patient and methods
Detailed methods can be found in Additional file 1:
Supplemental Methods.
Ethics, consent and permissions
Informed consent to publish the results of this autopsy
study was obtained from the patient’s next of kin.
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Case presentation
A 72-year-old Italian-American male demonstrated pro-
gressive cognitive decline over 13 years punctuated by
multiple encephalopathic episodes that included headache,
confusion, ataxia and short-term memory loss. Six years
prior to death, radiographic workup revealed superficial
siderosis and an arteriovenous malformation involving the
thoracolumbar spinal cord (T11), findings which were
previously reported [23]. Resection of the arteriovenous
malformation alleviated the patient's encephalopathic epi-
sodes but did not ameliorate his moderate ataxia nor halt
his progressive cognitive decline. A follow-up visit three
months after his resection was notable for severe cognitive
impairment. He scored a 9 on the 30-point mini-mental
state examination with deficits in language, memory, ex-
ecutive function, and visuospatial skills. A complete aut-
opsy demonstrated that the patient died of aspiration
pneumonia, sepsis and multiple organ system failure.
Mild to moderate amyloidosis was also noted in the sys-
temic organs examined histologically (Additional file 1:
Table S1). A standard dementia neuropathologic workup
[24] was performed.
Histopathology
Tissue sections (6 μm thickness) were stained with
hematoxylin and eosin. Immunoperoxidase reactions
with the following antibodies were performed with
standard methods: α-synuclein (Cell Signaling #2642,
1:1000); amyloid-beta (clone 6F/3D, Dako, M0872,
1:400; clone 4G8, BioLegend, SIG-39220, 1:500); Fused
in sarcoma (FUS; Sigma, HPA008784, 1:3000); glial fi-
brillary acidic protein (GFAP; Dako, Z0334, 1:2000);
myelin basic protein (Dako A0623, 1:400); phospho-
MAPT (clone AT8; Thermo Scientific, MN1020, 1:2000);
3-repeat isoform MAPT (3R MAPT, RD3; clone 8E6/C11,
Millipore, 05–803, 1:250); 4-repeat isoform MAPT (4R
MAPT, RD4; clone 1E1/A6, Millipore, 05–804, 1:250);
TDP-43 (Proteintech 10782-2-AP, 1:10,000); TTR (Dako
A0002, 1:4000). Special stains, including the modified
Bielschowsky stains, Gallyas silver stains, Luxol fast blue-
periodic acid Schiff stains, were also performed. Formalin-
fixed, paraffin-embedded (FFPE) tissues were sampled and
reprocessed for transmission electron microscopy (TEM)
using standard techniques.
Molecular analyses
APOE genotyping was performed on genomic DNA ex-
tracted from FFPE tissue sections via restriction frag-
ment analysis according to the method of Kamboh and
colleagues [25]. All 4 exons of the patient’s TTR gene
were sequenced from the same genomic DNA. Tissue
cores (3 mm diameter; 0.8 to 1.7 mg) punched from the
formalin-fixed, paraffin embedded tissue blocks were an-
alyzed by mass spectrometry (MS) [26].
Results
Gross examination of the 1390 g brain revealed golden-
brown discoloration and hardening of the leptomeninges
over the cerebral hemispheres and cisterns at the base of
the brain (Fig. 1a). There was mild cortical atrophy involv-
ing the frontal, temporal and parietal lobes, the insula and
the cerebellar vermis. There was minimal atrophy of the
hippocampus and no significant hydrocephalus ex vacuo.
Histologic sections of the leptomeninges revealed severe
congophilic vascular and extravascular amyloid deposits
(Fig. 1b,c) with minimal extension along cortical penetrat-
ing vessels. Granulomatous angiitis was not seen. In the
basilar cisterns, the vascular amyloid was associated with
moderate to severe vasculopathy with smooth muscle
loss and double barrel vascular profiles. Extensive sub-
pial amyloid was identified in the cerebral hemispheres
(Fig. 1d) and superficial cerebellar folia. Extensive intra-
ventricular congophilic amyloid aggregates and sube-
pendymal amyloid deposits involving the alveus (Fig. 1e)
and fornix (Fig. 1f ) were seen.
We employed the immunostains at our disposal,
Amyloid-beta and TTR, to attempt to identify the amyloid
protein in FFPE tissue block sections with negative results
(Additional file 1: Figure S1a, b). However, TEM images
demonstrated leptomeningeal amyloid fibrils that resem-
ble previously reported TTR amyloid fibrils (Additional
file 1: Figure S1c) [27]. We subsequently employed MS-
based proteomic analysis on core samples of the amyloid-
laden leptomeninges harvested from the paraffin blocks.
The most abundant protein identified by MS in the
meningovascular amyloid samples was TTR (Additional
file 1: Figure S2a). Extracted ion chromatograms (EICs)
demonstrated that mutant Y69H TTR comprised over
80 % of the of TTR peptides T49-K70. TTR was not de-
tected in the control brain parenchyma samples from the
basis pontis and subcortical white matter. Furthermore,
TTR was not detected in a sample of the insular cortex,
demonstrating that amyloidogenic TTR does not pene-
trate past the subpial space into the cortical paren-
chyma. We sequenced the patient’s TTR gene exons and
detected a heterozygous T to C point mutation in the
first nucleotide position of codon 69, exon 3, which en-
codes for the amino acid substitution of tyrosine for his-
tidine (Additional file 1: Figure S2b). Exons 1, 2 and 4
demonstrated wild type sequences. The patient’s APOE
genotype was determined to be E2/E3 (Additional file 1:
Figure S2c).
We further investigated the brain for neuropathology to
explain his dementia. We hypothesized that the prominent
subependymal amyloidosis (Fig. 1e,f) might damage hippo-
campal efferent tracts that line the ventricles, including the
alveus, fimbria and fornix. Special stains for myelin, includ-
ing LFB/PAS and myelin basic protein immunohistochem-
istry, demonstrated severe myelin pallor in the alveus and
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Fig. 1 Meningovascular and ventricular amyloidosis associated with Tyr69His substitution in TTR. a Gross images demonstrating golden-brown
discoloration of the leptomeninges of the cerebral hemispheres and the cisterns at the base of the brain. A coronal section of the brain demonstrates
diffuse cortical atrophy, but very little hippocampal atrophy or ventricular dilatation. b A Congo red stain performed on the cerebral leptomeninges
highlights the vascular and extravascular amyloid deposits (inset, Congo red under epifluorescence microscopy with Texas red filter; original
magnifications of 40×). c Visualization of the Congophilic meningovascular amyloid under polarized light reveals the diagnostic apple-green
birefringence (Congo red; original magnification of 40×). d Subpial amyloid deposits in the insular cortex (H&E; original magnification of 40×).
e, f Subependymal amyloid deposits in the alveus (e; H&E; original magnification of 100×) and fornix (f; H&E; original magnification of 40×)
Fig. 2 Evidence of subependymal and subpial injury. Sections of hippocampal efferent tracts from our patient (a-d) were compared to age-matched
control cases (e-h). Luxol fast blue (LFB) stains demonstrate myelin pallor in Ammon’s horn (a, e; LFB; original magnification of 10×), the alveus
(b, f; LFB; original magnification of 100×) and fimbria (c, g; LFB; original magnification of 100×) in TTR amyloidosis compared to the age matched
hippocampus. Myelin basic protein (MBP) immunostains demonstrated similar myelin pallor in the fimbria (d, h; MBP; original magnification of 100×).
i. The superficial insular cortex demonstrated gliosis with eosinophilic bodies (arrows; H&E; original magnification of 100×), similar to those reported
in Herrick et al. [14], that were variably GFAP immunoreactive (j; GFAP; original magnification of 100×). Iron stains demonstrated siderosis in the upper
cortical layers of the superior temporal gyrus (k; iron stain; original magnification of 200×) and in the Bergmann glia of the atrophied cerebellar
vermis (l; iron stain; original magnification of 200×)
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fimbria compared to 2 age-matched autopsy brains with
no significant neuropathology (Fig. 2a-h). There was no
histologic evidence of subcortical leukoencephalopathy and
only a single, minute, remote cortical infarct was seen in a
section of the right postcentral gyrus (Additional file 1: Fig-
ure S5f). The lack of ischemic pathology is consistent with
pre-mortem 3 T magnetic resonance FLAIR images show-
ing no obvious white matter changes or microinfarcts
(Additional file 1: Figure S3a). We observed brisk gliosis in
the upper neocortical layers subjacent to the subpial
amyloid deposits (Fig. 2i,j). These findings suggest that
subependymal and subpial TTR amyloid deposits are as-
sociated with injury to the subjacent brain parenchyma,
including hippocampal efferent tracts and superficial
layers of the neocortex. Iron deposits were observed histo-
logically in the superficial neocortex, especially in sections
of the frontal and temporal lobes (Fig. 2k), and in the
Bergmann glia of the atrophied Purkinje cell layer of
the vermis (Fig. 2l). Pre-mortem GRE images also dem-
onstrate the superficial siderosis (Additional file 1:
Figure S3b). Recent or remote microvascular hemor-
rhages were not seen.
Phospho-MAPT immunostains (clone AT8) revealed
neurofibrillary tangles in Pre α cells of the entorhinal
cortex and focally moderate neurofibrillary tangles in the
pyramidal cells of the hippocampal CA1 sector, indicative
of Braak stage II or B1 transentorhinal stage of neurofibril-
lary degeneration (Additional file 1: Figure S4). Although
there were conspicuous AT8 immunoreactive (AT8ir)
threads surrounding the vestigial hippocampal sulcus
(Additional file 1: Figure S4c), we saw no tangles in CA2 or
the fascia dentata. Curiously, we also observed neocortical
tauopathy characterized by AT8ir threads and neuronal
somata. Most distinctive were subpial AT8ir granules,
globules and threads subjacent to the subpial TTR
amyloid deposits throughout the neocortex (Fig. 3a,b).
AT8ir threads and neurons and rare neurofibrillary tan-
gles were also found in the deeper levels of the neocor-
tex (Fig. 3c,d). Subpial and neocortical tauopathy was
most prominent in a section of the middle frontal gyrus
(Fig. 3), but was present throughout the neocortex in-
cluding primary motor and striate cortices (Additional
file 1: Table S2). The parenchymal threads and most of
the AT8ir neurons were not argyrophilic (Gallyas stains,
not shown). Scattered axons in the subcortical white
matter also demonstrated AT8 immunoreactivity, but
there was no apparent tauopathy in glial somata.
Immunostains for amyloid-beta (clones 6F3D and
4G8) demonstrated a complete absence of amyloid-beta
plaques in the neocortex (Additional file 1: Figure S5a).
Bielschowsky stains likewise revealed an absence of neo-
cortical neuritic plaques. We incidentally observed focal
sparse neuritic plaques, immunoreactive for amyloid-
beta and AT8, in the stratum oriens of the hippocampal
CA1 sector (not shown). These few focal neuritic pla-
ques were distinct from the TTR amyloid deposits in the
Fig. 3 Cortical tauopathy in TTR meningovascular amyloidosis. Phospho-MAPT (AT8) immunostains were performed to determine if TTR
meningovascular amyloidosis and dementia were associated with tauopathy. a, b Intense granular, threadlike and globular AT8 immunoreactivity was
observed in the molecular layer of the entorhinal cortex (a; AT8; original magnification of 100×) and frontal neocortex (b; AT8; original magnification of
100×) subjacent to subpial amyloid deposits (asterisk). c AT8ir threads and neurons were observed in deep layers of the frontal neocortex (AT8; original
magnification of 200×). d Rare neocortical neurofibrillary tangles were also seen (AT8; original magnification of 200×)
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alveus. Grade I cerebral amyloid-beta angiopathy was seen
in only a few leptomeningeal vessels with the 4G8 anti-
body (Additional file 1: Figure S5b) [28]. Immunostains
for α-synuclein (Additional file 1: Figure S5c), TDP-43
(Additional file 1: Figure S5d) and FUS (Additional file 1:
Figure S5e) revealed no abnormal neuronal inclusions.
Discussion
Several TTR substitutions are associated with biopsy-
or autopsy-proven meningovascular amyloidosis [6–22].
Many patients with these mutations suffer from demen-
tia and/or ataxia. Previously, Blevins and colleagues [19]
reported only sparse neocortical neuritic plaques and
amyloid-beta plaques and no evidence of hemorrhages
or siderosis in a non-demented patient from a Swedish
kindred with the Tyr69His TTR substitution. Post-
mortem neuropathologic dementia workups in cases of
meningovascular TTR amyloidosis with dementia have
not been reported in the literature. The neuropathologic
underpinnings of meningovascular amyloidosis-associated
dementia are therefore unknown.
To provide novel insights into the potential neuropatho-
logic substrates of dementia and ataxia in this disorder, we
present the postmortem neuropathologic findings from a
patient with dementia, ataxia and meningovascular amyl-
oidosis associated with the rare Tyr69His (Y69H) substitu-
tion in TTR. To our knowledge, our patient, whose
maternal and paternal ancestors originated from north-
west Italy, is not related to the prior 2 reported kindreds
with the Tyr69His TTR substitution from Sweden and
Saskatchewan [19–21]. Our histologic and MS data dem-
onstrate that TTR amyloid does not penetrate the cortex
and subcortical white matter. Rather, TTR amyloid is de-
posited in leptomeningeal vessels and in subpial and sube-
pendymal deposits. This observation strongly argues that
injuries to periventricular structures and superficial cortex
are likely relevant for the neurologic deficits. We observed
subependymal TTR amyloid and myelin loss in hippocam-
pal efferent tracts including the alveus, fimbria and fornix
that may underlie our patient’s memory deficit. We also
observed brisk reactive gliosis and dystrophic astrocytic
processes, which were previously noted by Herrick and
colleagues [14], in the superficial neocortex. Our findings
may implicate neuronal toxicity subjacent to subpial and
subependymal TTR amyloid deposits in the pathogenesis
of the dementia and ataxia.
A novel finding in this report is the association of neo-
cortical tauopathy with meningovascular TTR amyloid-
osis. AT8 immunostains revealed Braak stage II [29], or
transentorhinal B1 stage [24], of neurofibrillary degener-
ation based on the presence of neurofibrillary tangles in
the Pre α neurons of the entorhinal cortex and only a
few neurofibrillary tangles in the CA1 sector of the
hippocampus. These neurofibrillary tangles were
immunoreactive for both 3R and 4R MAPT and appeared
to have paired-helical filament ultrastructure. In our pa-
tient, whose APOE genotype was E2/E3, there were no
neocortical neuritic plaques, no neocortical Aβ deposits
and no hippocampal granulovacuolar degeneration. We
identified only focal sparse neuritic plaques of uncertain
significance in the stratum oriens of the hippocampal CA1
sector. In the absence of neocortical amyloid-beta and
neuritic plaques in our patient, the transentorhinal stage
neurofibrillary degeneration is indicative of early primary
age-related tauopathy (PART) [30].
Interestingly, we found AT8ir threads and neurons in
nearly all of the neocortical regions examined, including
the primary motor cortex and striate cortex, which are
classically considered the last to be affected by tauopathy
in PART and Alzheimer disease (AD). The density of
threads and neurons appeared increased over the levels
typically seen with Braak stage II PART. Furthermore, in
all sections of the neocortex, we observed distinctive
AT8ir granules, globules and threads in the molecular
layer subjacent to the subpial TTR amyloid deposits.
Thus, while we cannot be certain that all of the tau
pathology in our case is not related to PART, these ob-
servations suggest the possibility of a link between the
subpial amyloid and the neocortical tau pathology. Only
rare neocortical neurons showing staining consistent
with neurofibrillary tangles were seen, and overall, the
tauopathy was much less severe than the neocortical
tauopathy seen in patients with high AD neuropathol-
ogy [24]. However, given the association of isocortical
tauopathy/tangles with cognitive impairment in the eld-
erly [31] and evidence supporting a role for pMAPT in
the functional impairment of synapses [32], it is reason-
able to hypothesize that the neocortical tauopathy ob-
served in this case of meningovascular TTR amyloidosis
contributed to the cognitive impairment. Further studies
are needed to elucidate the prevalence and contribution of
neocortical tauopathy to dementia in meningovascular
amyloidosis, its potential relationship to PART and early
AD neuropathologic changes, and a possible causal or
contributory role for TTR amyloidosis in the neocor-
tical tauopathy.
We evaluated for co-morbid dementia neuropathol-
ogies and found no evidence of Lewy bodies, TDP-43
proteinopathy or FUS proteinopathy. Ischemic lesions,
which were reported in a kindred with an unspecified
TTR mutation [33], were not prominent in our case.
Our sections demonstrated only a solitary minute cor-
tical microvascular ischemic lesion in the postcentral
gyrus [31] and no evidence of ischemic white matter
degeneration, suggesting that a significant burden of is-
chemic lesions is not necessary for dementia in meningo-
vascular TTR amyloidosis. There was, however, evidence
of vascular damage and chronic hemorrhage from the
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meningovascular amyloid leading to toxic superficial side-
rosis [23], which likely contributed to his cognitive impair-
ment and ataxia.
Conclusion
In summary, we have described the neuropathologic aut-
opsy findings from a 72 year old male with variant Y69H
TTR meningovascular amyloidosis. Our findings suggest
that neocortical injury secondary to subpial TTR amyl-
oid, injury to hippocampal efferent tracts secondary to
subependymal TTR amyloid, and superficial siderosis
may play important roles in the cognitive impairment
and ataxia associated with variant TTR meningovascular
amyloidosis. Our case, which demonstrated early PART,
also showed neocortical tauopathy that was unusual for its
subpial distribution. Further autopsy studies on patients
with TTR meningovascular amyloidosis are necessary to
elucidate the significance of tauopathy in the cognitive im-
pairment and to further delineate the neuropathologic
changes that underlie dementia. A better understanding of
the pathogenic events leading to dementia in variant TTR
meningovascular amyloidosis may lead to novel treatment
strategies for this debilitating and fatal disease.
Additional file
Additional file 1: Supplemental Material. Supplemental Methods.
Table S1. Vascular TTR amyloid in sampled systemic organs. Table S2.
Comparison of TTR amyloid, pMAPT (AT8ir) and iron deposition across
brain regions. Figure S1. Immunohistochemical stains did not label the
amyloid protein. a. Amyloid-beta immunostains (clone 6F3D shown; clone
4G8 not shown) were negative in the meningovascular amyloid (Aβ; ori-
ginal magnification of 40×). b. A TTR immunostain is positive in the chor-
oid plexus epithelium but does not convincingly label the vascular
amyloid (TTR; original magnification of 40×). Staining of the intraventricu-
lar amyloid is equivocal. c. TEM image of leptomeninges (25,000×) dem-
onstrating dense aggregates of amyloid fibrils. Figure S2. Molecular
characterization of TTR amyloidosis. a. List of top 5 most abundant pro-
teins detected by MS in amyloid samples taken from the leptomeninges
of the prepontine cistern (Samples A1, A2) and cerebral hemispheres
(Samples A4, A5). Note the abundance of transthyretin/TTR in the amyloid
samples compared to control brain tissue samples of the basis pontis
(Samples C3a, C3b) and subcortical white matter (SWM; Samples C6, C7).
Interestingly, no transthyretin was detected in a core sample of the deep
layers of the insular cortex (IC; Sample I) just subjacent to the subpial
amyloid deposits demonstrated in Fig. 1d. Extracted ion chromatograms
(EIC) of the normal and mutated transthyretin peptide T49-K70 for amyl-
oid (A2, A4, A5) and control (C3, C6, C7) samples. Chromatographic peak
areas under curves (AUC) suggest that approximately 85 %-90 % of the
transthyretin protein in the amyloid regions exist in the mutated Y69H
form corresponding to the mutant TTR allele. b. DNA sequencing results
demonstrated the wild type TTR allele in 2 of 5 PCR clones from the cere-
bellar cortex and the mutant Y69H allele in 3 of 5 PCR clones. c. The
APOE genotype of this patient, determined by restriction fragment length
analysis, is E2/E3. Samples from this case (red font) were run alongside
cases with known APOE genotypes (black font). Figure S3. Premortem
3T MRI images. a. FLAIR images demonstrating no evidence of ische-
mic subcortical leukoencephalopathy. The 3T images lack the resolution
to examine for the white matter loss in the hippocampal outflow tracts
(alveus, fimbria and fornix) seen by histology. b. GRE images demonstrat-
ing superficial siderosis in the cerebellar cortex and cerebrum (arrows).
Figure S4. Limbic tauopathy was compatible with early primary age-
related tauopathy (PART). AT8 immunoperoxidase stains demonstrated ro-
bust AT8ir pre-α cells of the entorhinal cortex (a, AT8; original magnifica-
tion of 10×; b, AT8; original magnification of 100×) and few AT8ir neurons
in the CA1 sector of the hippocampus (c, AT8; original magnification of
10×), compatible with Braak stage II (B1) PART. Prominent AT8ir threads
were seen around the vestigial hippocampal sulcus (c). Entorhinal cortex
tangles labeled with antibodies to 3R MAPT (d; original magnification of
100×) and 4R MAPT
(e; original magnification of 100×), again compatible with PART. f. TEM
image of entorhinal cortex neurofibrillary tangle (70,000×) from formalin-
fixed tissue reprocessed for TEM revealing filamentous inclusions that are
compatible with paired helical filaments. Figure S5. Additional neurode-
generation workup. a. Amyloid-beta immunostain (clone 4G8) demon-
strated complete absence of neocortical plaques (4G8; original
magnification of 200×). b. Very mild, focal cerebral amyloid-beta angiopa-
thy was revealed by the 4G8 antibody (original magnification of 200×). c.
α-synuclein immunostains revealed no cortical Lewy body neuropathol-
ogy (α-synuclein; original magnification of 200×). d. TDP-43 immunostains
revealed no abnormal threads or neuronal cytoplasmic or nuclear inclu-
sions (TDP-43; original magnification of 200×). e. FUS immunostains re-
vealed no abnormal neuronal cytoplasmic inclusions (FUS; original
magnification of 200×). Positive control slides from AD, Lewy body disease,
FTLD-U (TDP-43) and FTLD-U (FUS) were employed to demonstrate the ef-
ficacy of all of these antibodies (not shown). f. Only a single small remote
cortical infarct was seen in a section of the precentral gyrus (H&E; original
magnification of 10×). No other significant cerebrovascular disease path-
ology was present on standard dementia workup sections.
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